AU2017200331B2 — Sublingual films
Assigned to Sumitomo Pharma America Inc · Expires 2018-12-13 · 7y expired
What this patent protects
A sublingual pharmaceutical composition in unit dosage form having a first portion comprising a dopamine agonist or an acid addition salt thereof, and a second portion comprising a pH neutralizing agent, wherein said dopamine agonist is selected from apomorphine, bromocriptine, c…
USPTO Abstract
A sublingual pharmaceutical composition in unit dosage form having a first portion comprising a dopamine agonist or an acid addition salt thereof, and a second portion comprising a pH neutralizing agent, wherein said dopamine agonist is selected from apomorphine, bromocriptine, cabergoline, dihydroergocryptine, lisuride, piribedil, pergolide, pramipexole, rotigotine, and ropinirol. The dosage form may be a film comprising a mixture of a low and a high molecular weight cellulose derivative. Also included is a method of forming a bilayer film of said dopamine agonist or acid addition salt thereof, comprising the dopamine agonist, low and a high molecular weight cellulose derivatives, plasticizing agent and hydrolysed starch.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.